Introduction {#ss1}
============

Because patients with osteoarthritis (OA) outnumber those with rheumatoid arthritis (RA) or even osteoporosis, there is a need to identify molecular markers and develop new treatments against this disease. The primary pathology of OA is degeneration of the articular cartilage matrix. Recent epidemiological investigations have revealed that acetabular dysplasia is the most important factor involved in OA onset in the hip joint (Jingushi et al., [@b20]). Obesity has also been identified as closely associated with OA in knee and hip joints. Such mechanical stresses cause abnormalities in the metabolism of articular cartilage, leading to degeneration of the cartilage matrix. Although this degeneration has been attributed to various possible mediators, including proteases, hypoxia inducible factor-2α (Hirata et al., [@b18]; Saito et al., [@b34]; Saito & Kawaguchi, [@b35]), reactive oxygen species (ROS) (Xie et al., [@b48]), and the complement system (Wang et al., [@b41]), the precise molecular pathogenic mechanism of OA remains unknown. Accordingly, current treatment practices are limited to surgical procedures incorporating prosthetic joint replacement with medical therapies limited to symptom control (Yamada et al., [@b49]). Curative non-surgical treatments remain to be established. OA is associated with a particularly high morbidity rate among the elderly. Because surgical procedures can be major physical challenges for the elderly owing to complications from cardiovascular disease and diabetes, the demand for the development of medical therapies for OA is also crucial from the perspective of health economics.

Biomarkers within the blood and urine can reflect the status and possible future progression of a disease. As indicators of normal biological and pathological processes and as pharmacological indicators of therapeutic interventions, biomarkers allow measurements and evaluations to be made objectively (Gharbi et al., [@b14]). Currently, biomarkers are utilized clinically in the diagnosis of musculoskeletal diseases such as RA and osteoporosis. Moreover, biomarkers are used to monitor disease progression, make prognoses and evaluate the effectiveness of new drug treatments. Measurements of biomarkers in bodily fluids such as blood or urine are a simple means of evaluating a disease condition. In recent years, there has been a high demand for exploration of biomarkers for a variety of diseases (Kraus, [@b26]).

Recently, an increasing number of studies have investigated the diagnosis and prognosis of OA by measuring biomarkers present in the blood serum, urine, or synovial fluid of OA patients (Kraus, [@b26]). Biomarkers allow diagnosis of OA in early stages when macroscopic changes are few and difficult to detect, which enables highly objective diagnoses, compared to diagnoses using radiography, and provides quantitative evaluation of disease severity. Any protein with a differential expression between regular healthy cartilage and OA cartilage is a candidate diagnostic marker of OA. Cartilage oligomeric matrix protein (COMP) has been studied as a diagnostic marker, because it is a cartilage matrix component that is released into the blood and urine during cartilage degeneration (Kato et al., [@b22]). Fragments of C-terminal cross-linked telopeptide type II collagen (CTX-II), type II procollagen carboxy-propeptide (CPII), type II collagen-related neoepitope (C2C) and hyaluronic acid (HA) are examples of other possible candidates of diagnostic markers for OA. CTX-II and C2C are products of sequential degradation by several proteases originating from the cartilage matrix, including matrix metalloproteinase (MMP)-1, MMP-8 and MMP-13 (Conrozier et al., [@b8]).

Proteomic analysis is a research method to catalog all proteins inside cells and organisms. This method can elucidate protein structure and function as well as protein interactions inside the cell. In the general method of proteomics, samples are electrophoresed and the differential proteins are picked up as spots. After trypsin digestion, proteins are analyzed by mass spectrometry (Chambers et al., [@b4]). Proteins that are not included in spot areas cannot be detected. Furthermore, detected proteins with a low abundance cannot be used in quantitative analysis by conventional methods.

The isobaric tags for the relative and absolute quantitation (iTRAQ) method allow a more comprehensive analysis. Whole samples undergo trypsin digestion and then labeling with an iTRAQ reagent for analysis by mass spectrometry based on shotgun proteomics (Aggarwal et al., [@b1]; Ross et al., [@b33]). More than two digested samples can be labeled with separate reagents to perform quantitative analysis. This method has a high sensitivity and it is possible to detect low-abundance protein.

General proteomic analysis frequently identifies abundant proteins (ribosomal, proteasomal and cytoskeletal proteins as well as molecular chaperons) as biomarkers. However, it is well known that rare proteins such as secretory proteins and kinases are also important for various biological functions. In this study, among the lysates eluted through a random peptide column, we detected molecular variations in low-abundance proteins that were difficult to identify by conventional methods.

Proteomic analysis of serum from OA patients has revealed increased levels of the C-terminal end product of the V65 vitronectin subunit, C3f peptide, and connective tissue-activating peptide III (CTAPIII) (de Seny et al., [@b9]), as well as HPT (Fernandez-Costa et al., [@b11]). COMP, apolipoprotein, haptoglobin precursor, calgranulins, defensins and thymosins have been detected in synovial tissue (Kong, [@b24]; Kriegsmann et al., [@b27]). Furthermore, OA cartilages have been analyzed by the MALDI-based imaging technique. As a result, OA-related peptides and proteins were detected in deep cartilage (Cillero-Pastor et al., [@b7]). In previous studies, serum biomarkers have been identified by iTRAQ in OA patients (Fernandez-Puente et al., [@b12]; Song et al., [@b38]). In comprehensive proteomic analyses, because it is possible that diseases other than OA in patients can affect components in serum and urine, we used cartilage as samples in the current study. This is the first report of iTRAQ methods to assess OA and control cartilages to find new molecular markers for OA.

Materials and methods {#ss2}
=====================

This study was approved by the steering committee and conducted under the guidelines for clinical studies of Fujita Health University. Human cartilage from OA patients and control subjects was obtained with informed consent.

Patients and articular cartilage {#ss3}
--------------------------------

Control samples were obtained from 6 patients with femoral neck fracture (4 male and 2 female patients). The samples were collected from femoral head cartilage during bipolar femoral head replacement at Fujita Health University Hospital. OA cartilage samples were obtained from 17 patients with OA (5 male and 12 female patients). These samples were collected from the femoral heads, femoral condyles, and tibial plateaus of patients with primary OA, who underwent total hip or knee replacement surgery at Fujita Health University Hospital ([Table 2](#t2){ref-type="table"}).

Protein preparation {#ss4}
-------------------

Samples were snap frozen at −80 °C and cut into 10 µm sections by using a cryo-microtome (CM1900; Leica, Grove, IL). The sectioned samples were homogenized by sonication (T10 basic Disperser/Homogenizer; IKA) in RIPA buffer (10 mL of 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate and 0.1% SDS/g cartilage). Then, the samples were centrifuged at 20 000 × *g* at 4 °C for 10 min, and the supernatant was used for analysis. Amicon Ultra Centrifuge Filters 10 K (Millipore, Billerica, MA) were used to concentrate proteins by centrifugation at 5000 × *g*. Concentrated samples were stored at −80 °C until use. A random peptide column (Proteominer; BIO-RAD, Hercules, CA) was used to prepare samples for iTRAQ. High-abundance proteins in these samples were excluded, while rare proteins were collected. Eluted samples were concentrated by Amicon Ultra Centrifuge Filters 10 K by centrifugation at 14 000 × *g*.

iTRAQ method {#ss5}
------------

The protein samples were buffer exchanged and concentrated using 4-mL spin concentrators with a 5-kDa molecular weight cut-off according to supplied protocols (Agilent Technology, Santa Clara, CA). Briefly, the samples were centrifuged at 2600 × *g* for 20--30 min at 4 °C. The protein samples were then buffer exchanged in the appropriate buffer containing 0.5 M triethylammonium bicarbonate for further analysis. The protein concentration of each sample was measured using a BCA Protein Assay Kit (Pierce, Rockford, IL). From each sample, 100 µg of protein was reduced, alkylated, and digested prior to labeling with iTRAQ reagent according to the manufacturer's instructions (AB Sciex, Framingham, MA). Digested proteins prepared from each sample were labeled with iTRAQ reagent, and then pooled and washed according to the manufacturer's instructions (AB Sciex, Framingham, MA). Peptides were subjected to a trap and reverse-phase (RP) analytical column by using a gradient of 0--50% solvent B in solvent A over 140 min (solvent A: 0.1% trifluoroacetic acid \[TFA\] and 2% acetonitrile; solvent B: 0.1% TFA and 70% acetonitrile) and 50--100% solvent B for 5 min at a flow rate of 300 nL/min. The RP analytical column eluent was spotted onto a MALDI sample plate by using a DiNa Direct Nano-flow LC/MALDI system (KYA Tech, Tokyo, Japan) and analyzed by a 4800 mass spectrometer (AB Sciex, Framingham, MA). Relative protein abundance was determined using MS/MS scans of the iTRAQ-labeled peptides. iTRAQ-labeled peptides were fragmented under collision-induced dissociation conditions to generate fragment ions that provided sequence information for the peptide and reporter ions. Thus, the identity of the protein from the analyzed peptide was confirmed, and the ratios of the peak areas of iTRAQ reporter ions were used to compare the relative abundance of the protein identified in the sample. ProteinPilot v4.0 (AB Sciex, Framingham, MA) was used for data analysis using NCBI and SWISS-PROT databases.

Western blot analysis {#ss6}
---------------------

Protein samples (35 µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred onto polyvinylidene difluoride membranes. The membranes were blocked in 10% goat serum for 1 h at room temperature. Then, the membranes were probed with anti-LECT2 (ab89835, 1/250 dilution; Abcam), or anti-BAALC (H00079870-M01, 1/100 dilution; Abnova) antibodies for 1 h at room temperature, followed by incubation with a horseradish peroxidase-conjugated secondary antibody, and then chemiluminescence detection by ECL plus. Captured images were analyzed using a LAS4000 (Fuji Film) and Multi Gauge v2.0 (Fuji Film). For the anti-PRDX6 (MAB3490, 1/250 dilution; R&D SYSTEMS) antibody, the membrane was blocked in 5% skim milk. An XL-SAP Kit (APRO Science) was used for secondary antibody reactions. As internal controls, 35 µg protein samples (control: *n* = 5; OA: *n* = 16) were separated by SDS-PAGE, and then, SYPRO ruby protein gel staining (Invitrogen, Carlsbad, CA) was performed according to the manufacturer's instructions. Gel images were taken by a Typhoon scanner (GE Healthcare, Tyrone, PA). Total intensity measurements of 10--200 kDa proteins were analyzed by image analysis software (ImageJ, Wayne Rasband (NIH), DC). For quantification of western blot data, each protein signal was quantitated and normalized by the total protein intensity.

Kellgren--Lawrence grade (Kellgren & Lawrence, [@b23]) {#ss7}
------------------------------------------------------

Grade 0: normal

Grade 1: doubtful narrowing of the joint space and possible osteophytic lipping

Grade 2: definite osteophytes and definite narrowing of the joint space

Grade 3: moderate multiple osteophytes, definite narrowing of the joint space, and some sclerosis and possible deformity of the bone contour

Grade 4: large osteophytes, marked narrowing of the joint space, and severe sclerosis and definite deformity of the bone contour.

Results {#ss8}
=======

For the iTRAQ method, a control sample was obtained from a patient with femoral neck fracture (female, 46 years old). An OA sample was also obtained from a patient with hip OA (female, 59 years old). These samples were collected during arthroplastic surgeries at Fujita Health University Hospital.

Before applying the iTRAQ method, we used random peptide columns (BIO-RAD, Hercules, CA, Proteominer) to concentrate rare proteins in extracts from control and OA cartilages. Eluted proteins from random peptide columns were then analyzed by iTRAQ ([Figure 1A](#f1){ref-type="fig"}).Figure 1.Result of shotgun proteomics based on iTRAQ method. (A) Experimental scheme. (B) Venn diagram showing the ratio of proteins that were included in OA and control cartilages based on the results of iTRAQ method. The diagram defines increased proteins for which OA/control ratio was more than 1.25 and decreased proteins for which the OA/control ratio was less than 0.75.

We detected a total of 310 proteins ([Table 1](#t1){ref-type="table"}), of which 55 proteins showed increased levels in OA cartilage and 21 proteins showed decreased levels in OA cartilage compared with the levels in the control group ([Figure 1B](#f1){ref-type="fig"}). We selected 3 proteins (LECT2, BAALC and PRDX6) from the 76 proteins with variable levels, which had not been previously reported as biomarkers for OA and could be detected by western blotting with available antibodies. We next performed statistical analysis of western blot data of these proteins. Control samples were obtained from 5 patients with femoral neck fracture (4 male and 1 female patients). OA samples were obtained from 16 patients (5 male and 11 female patients) ([Table 2](#t2){ref-type="table"}).

###### 

The articular cartilage proteome.

  No.                                           Accession       Name                                                       Ratio of OA to control
  --------------------------------------------- --------------- ---------------------------------------------------------- ------------------------
  Top 30 of increased protein in OA cartilage                                                                              
  1                                             gi\|179665      Complement component C3                                    2.681
  2                                             gi\|119605141   Cartilage oligomeric matrix protein, isoform CRA_a         2.391
  3                                             gi\|158257468   Unnamed protein product                                    1.911
  4                                             gi\|158255148   Unnamed protein product                                    1.821
  5                                             gi\|1000745     Pro-a2(XI)                                                 1.791
  6                                             gi\|62205353    Matrix Gla protein                                         1.758
  7                                             gi\|193787240   Unnamed protein product                                    1.756
  8                                             gi\|118573093   Ovochymase-1                                               1.656
  9                                             gi\|4220894     Transcriptional co-activator CRSP70                        1.652
  10                                            gi\|50295448    Platelet phospholipase A2                                  1.633
  11                                            gi\|194377958   Unnamed protein product                                    1.632
  12                                            gi\|119220552   Protein sidekick-1 precursor                               1.623
  13                                            gi\|119604277   Pleiotrophin                                               1.596
  14                                            gi\|119587667   hCG2045237                                                 1.573
  15                                            gi\|940106      T-cell receptor delta chain                                1.571
  16                                            gi\|34364882    Hypothetical protein                                       1.527
  17                                            gi\|49113217    HHIP-like 2                                                1.524
  18                                            gi\|348041283   C-type lectin domain family 3 member A isoform 1           1.514
  19                                            gi\|62420929    Actin-like protein                                         1.503
  20                                            gi\|118763987   PRSS3 protein                                              1.471
  21                                            gi\|193786062   Unnamed protein product                                    1.435
  22                                            gi\|18307851    Angiogenin                                                 1.433
  23                                            gi\|62897225    Transforming growth factor, beta-induced, 68 kDa variant   1.425
  24                                            gi\|68563369    Solute carrier family 4, anion exchanger, member 1         1.414
  25                                            gi\|21757045    Unnamed protein product                                    1.411
  26                                            gi\|59806345    Leukocyte cell-derived chemotaxin-2 precursor              1.389
  27                                            gi\|1017427     Elastic titin                                              1.381
  28                                            gi\|119609838   Phosphatidylserine receptor, isoform CRA_d                 1.376
  29                                            gi\|609342      Nucleophosmin-anaplastic lymphoma kinase fusion protein    1.369
  30                                            gi\|21755876    Unnamed protein product                                    1.341
  Top 30 of decreased protein in OA cartilage                                                                              
  1                                             gi\|1340142     Alpha1-antichymotrypsin                                    0.402
  2                                             gi\|13171812    Immunoglobulin heavy chain variable region                 0.415
  3                                             gi\|189054134   Unnamed protein product                                    0.554
  4                                             gi\|67190163    Proteoglycan 4 isoform A                                   0.598
  5                                             gi\|332164775   Pyruvate kinase isozymes M1/M2 isoform c                   0.608
  6                                             gi\|56205585    S100 calcium binding protein A1                            0.629
  7                                             gi\|51094573    Procollagen C-endopeptidase enhancer                       0.632
  8                                             gi\|53690154    Small nuclear ribonucleoprotein polypeptide B              0.649
  9                                             gi\|114676256   Hyaluronan and proteoglycan link protein 4                 0.661
  10                                            gi\|296011023   Stromal cell-derived factor 1 isoform delta                0.685
  11                                            gi\|114656687   Protein disulfide-isomerase A3 isoform 1                   0.685
  12                                            gi\|14595132    Raichu404X                                                 0.695
  13                                            gi\|312005      Small nuclear ribonucleoprotein E                          0.702
  14                                            gi\|194374101   Unnamed protein product                                    0.702
  15                                            gi\|119622424   Aggrecan 1                                                 0.722
  16                                            gi\|189069324   Unnamed protein product                                    0.728
  17                                            gi\|134254698   Peroxiredoxin 6                                            0.741
  18                                            gi\|54303904    Aging-associated gene 6 protein                            0.754
  19                                            gi\|62898165    Biglycan preproprotein variant                             0.759
  20                                            gi\|119586853   hCG2044782, isoform CRA_b                                  0.761
  21                                            gi\|32891795    Clusterin                                                  0.761
  22                                            gi\|48146501    IL17B                                                      0.762
  23                                            gi\|662841      Heat shock protein 27                                      0.771
  24                                            gi\|194382308   Unnamed protein product                                    0.772
  25                                            gi\|95115683    Hemoglobin alpha 1-2 hybrid                                0.774
  26                                            gi\|215274249   Fibulin-1                                                  0.784
  27                                            gi\|30354619    YWHAZ protein                                              0.787
  28                                            gi\|2204207     Glutathione S-transferase                                  0.791
  29                                            gi\|74761482    Epithelial splicing regulatory protein 2                   0.793
  30                                            gi\|21264602    Laminin subunit alpha-5 precursor                          0.801

The top 30 proteins that were increased or decreased in OA cartilage on iTRAQ method were extracted.

###### 

Characteristics of the OA patients and controls in this study.

  No                                                             Sample    Age   Gender   Height   Weight   BMI   K-L Grade   Joint
  -------------------------------------------------------------- --------- ----- -------- -------- -------- ----- ----------- -------
  *A* Patients list that was used in the iTRAQ analysis                                                                       
   1                                                             Control   46    F        156      55       23    --          --
   2                                                             OA        59    F        150      51       23    IV          Hip
  *B* Patients list that was used in the Western Blot analysis                                                                
   1                                                             Control   70    M        165      32.7     12    --          --
   2                                                             Control   70    M        158      52.7     21    --          --
   3                                                             Control   31    F        162      46       17    --          --
   4                                                             Control   39    M        180      81.5     25    --          --
   5                                                             Control   77    M        164      52       19    --          --
   6                                                             OA        75    M        159.5    70       27    III         Hip
   7                                                             OA        60    F        153      49       20    III         Hip
   8                                                             OA        56    F        156.8    56.2     22    IV          Hip
   9                                                             OA        52    M        173      73.8     24    III         Hip
   10                                                            OA        63    F        159      59       23    IV          Hip
   11                                                            OA        67    F        165      62.5     22    III         Knee
   12                                                            OA        74    F        147.8    54       24    IV          Knee
   13                                                            OA        87    F        151      50       21    IV          Knee
   14                                                            OA        82    F        135      49.7     27    IV          Knee
   15                                                            OA        79    F        143.7    37.7     18    III         Knee
   16                                                            OA        76    M        152      52       22    IV          Knee
   17                                                            OA        75    F        153      57.4     24    IV          Knee
   18                                                            OA        77    F        146.5    64       29    III         Knee
   19                                                            OA        63    M        162      69.1     26    III         Knee
   20                                                            OA        77    M        174.3    59.7     19    III         Knee
   21                                                            OA        81    F        149      50.3     22    II          Knee

We found that the expression levels of LECT2 (leukocyte cell-derived chemotaxin-2) were significantly higher in OA cartilage (LECT2: control, *n* = 5; OA, *n* = 16; *p* = 0.005). BAALC (brain and acute leukemia, cytoplasmic) expression was increased in OA cartilage compared with that in control cartilage (BAALC: control, *n* = 5; OA, *n* = 16; *p* = 0.051). PRDX6 (peroxiredoxin-6) expression was significantly reduced in OA cartilage compared with that in controls (PRDX6: control, *n* = 5; OA, *n* = 16; *p* = 0.011) ([Figure 2A and B](#f2){ref-type="fig"}).Figure 2.Western blot analysis of LECT2, BAALC and PRDX6. (A) We confirmed the protein expression levels of LECT2, BAALC and PRDX6 in OA and control. Protein gel was stained with SYPRO ruby. (B) Statistical analysis of western blot. Quantities are indicated relative to the average value of each protein level in controls. \**p* \< 0.05, statistically significant differences between OA and control, as determined by Student's *t*-test. Error bars indicate SEM. LECT2 (control, *n* = 5; OA, *n* = 16; *p* = 0.005), BAALC (control, *n* = 5; OA, *n* = 16; *p* = 0.051), PRDX6 (control, *n* = 5; OA, *n* = 16; *p* = 0.011). (\#) *p* = 0.051.

We next investigated whether the expression levels of LECT2, BAALC and PRDX6 proteins in OA patients were associated with the trends in each parameter, including age, Kellgren--Lawrence grades, height, body mass index (BMI), gender and joint site ([Figure 3A--F](#f3){ref-type="fig"}). People over 65 years of age were defined as elderly in Japan. There was a significant difference in age and LECT2 expression in patients over 65 years of age (*p* = 0.0012). BAALC and PRDX6 showed almost no difference in expression ([Figure 3A](#f3){ref-type="fig"}). In terms of Kellgren--Lawrence grade, there were almost no differences in LECT2, BAALC and PRDX6 expression ([Figure 3B](#f3){ref-type="fig"}). To compare height, we divided the patients into groups of \>160 cm or \<160 cm. According to the annual health report of the Ministry of Health, Labour and Welfare of Japan in 2011, 160 cm was considered as the standard height for men and women over 20 years of age. We found a mild correlation in the LECT2 protein level between patients in the two groups. LECT2 expression tended to be up-regulated in patients over 160 cm (*p* = 0.057). There were almost no differences in BAALC and PRDX6 expression ([Figure 3C](#f3){ref-type="fig"}). On the other hand, BMI calculated according to the criteria of JASSO (the Japan Society for the Study of Obesity, 2002), which defines a BMI of \>25 kg/m^2^ as obese. LECT2, BAALC and PRDX6 showed almost no differences in expression ([Figure 3D](#f3){ref-type="fig"}). In evaluation by gender, there was almost no difference in LECT2, BAALC and PRDX6 expression ([Figure 3E](#f3){ref-type="fig"}). Next, we compared differences between joint sites (knee versus hip). BAALC expression was higher in knee joints, but it was not statistically significant ([Figure 3F](#f3){ref-type="fig"}).Figure 3.Experimental correlation between LECT2 protein levels and Age in OA patients. (A) Age (\>65, *n* = 11; \<65, *n* = 5; LECT2, *p* = 0.012; BAALC, *p* = 0.397; PRDX6, *p* = 0.166). (B) K-L Grade (\>IV, *n* = 8; \<III, *n* = 8; LECT2, *p* = 0.401; BAALC, *p* = 0.282; PRDX6, *p* = 0.131). (C) Height (\>160 cm, *n* = 4, \<160 cm, *n* = 12; LECT2, *p* = 0.057; BAALC, *p* = 0.107; PRDX6, *p* = 0.482). (D) BMI (\>25, *n* = 4; \<25, *n* = 12; LECT2, *p* = 0.298; BAALC, *p* = 0.301; PRDX6, *p* = 0.330). (E) Gender (male, *n* = 5; female, *n* = 11; LECT2, *p* = 0.420; BAALC, *p* = 0.284; PRDX6, *p* = 0.304). (F) Hip or Knee (hip, *n* = 5; knee, *n* = 11; LECT2, *p* = 0.338; BAALC, *p* = 0.217; PRDX6, *p* = 0.106). \**p* \< 0.05, statistically significant differences between \>65 and \<65, as determined by Student's *t*-test. Error bars indicate SEM. (\#) *p* = 0.057. Quantities are indicated relative to the average value of each protein level in controls.

Discussion {#ss9}
==========

In this study, we identified three new molecules that show expression differences between patients with OA and those with femoral neck fracture.

LECT2 is a neutrophil chemotactic factor expressed mainly in the liver (Yamagoe et al., [@b50]). It is a multifunctional protein involved in liver regeneration and immunocompetence. LECT2 is an effector of β-catenin-induced hepatitis that can progress to a precancerous lesion of hepatocellular carcinoma (Anson et al., [@b2]). A correlation has been observed between vascular invasion of hepatocellular carcinomas and a decline in LECT2 expression (Ong et al., [@b30]). There is a link between the disease severity of RA and LECT2 polymorphism in Japan (Kameoka et al., [@b21]), and LECT2 is an inhibitor of collagen-induced arthritis in mice (Okumura et al., [@b29]). LECT2 is also present in cartilage and it is identical to chondromodulin-II that has been purified from bovine epiphyseal cartilage. Moreover, LECT2 stimulates chondrocyte growth and matrix formation *in vitro* (Hiraki et al., [@b17]; Shukunami et al., [@b37]). In the present study, a significant increase in LECT2 expression was observed in OA cartilage (*p* = 0.005).

The receptor for LECT2 is C-type lectin DC-SIGN (CD209), an antigen receptor expressed in dendritic cells (DCs) of the skin, mucosal tissues and lymphatic tissues such as the tonsils, lymph nodes and spleen. It is also expressed in monocyte-induced DCs (Chen et al., [@b5]). CD209 is highly expressed in inflammatory cells of the synovial membrane in RA patients, and has been found in the synovial membrane of OA patients (van Lent et al., [@b39]). The expression of CD209 depends on interleukin-4, and is inhibited by interferon, transforming growth factor-β, and anti-inflammatory drugs (Relloso et al., [@b32]). These observations indicate an involvement of LECT2 in the pathophysiologies of OA and RA.

The Wnt/β-catenin pathway is known to positively regulate LECT2 expression in the liver (Ovejero et al., [@b31]). An OA-like phenotype is induced by increased expression of the β*-catenin* gene in the cartilage of mouse models, suggesting that the Wnt/β-catenin pathway is associated with OA (Wu et al., [@b47]). Therefore, an association between increased LECT2 expression in OA and the Wnt/β-catenin pathway is possible. However, iTRAQ performed in the present study did not detect Wnt or β-catenin proteins. Therefore, the cause of the variation between control and OA groups could not be determined.

Although further investigation is required to determine whether increased LECT2 expression in OA operates positively or negatively during disease onset and progression, we propose that identification of another molecule that shows increased expression in OA patients is highly valuable. LECT2 may represent a possible diagnostic marker of OA.

When the expression level of LECT2 was compared against various parameters in OA patients, LECT2 levels were found to be increased significantly in patients over 65 years of age (*p* = 0.012). When considering patients over 160 cm in height (*p* = 0.057), no significant difference in LECT2 levels was found, but a tendency toward increased expression was apparent. Although no correlation was observed among height, age, and other OA biomarkers, a relationship has been suggested between *GDF5*, which has been associated with OA, and height in humans (Williams et al., [@b44]). Therefore, the level of LECT2 may rise according to age. For this reason, we recalculated the expression level of LECT2 in OA and control cartilages by excluding cases in which the patients were under 65 years of age. As a result, we found significant up-regulation of LECT2 expression in the OA group compared with that in the control ([Figure 4](#f4){ref-type="fig"}).Figure 4.The level of LECT2 in control and OA patient at over 65 years of age. We recalculated expression level of LECT2 in OA and control cartilage by excluding the case of under 65 years of age. LECT2 was increased in OA with a significant difference compared with control (Control *n* = 3, OA *n* = 11). \**p* \< 0.05, as determined by Student's *t*-test. Error bars indicate SEM.

BAALC includes 6 isoforms and is abundant in acute myelogenous leukemia (AML) cells and the brain. Currently, it is being studied extensively as a diagnostic or prognostic marker for AML. There have also been reports of a correlation between BAALC and AML prognosis (Langer et al., [@b28]). Histone post-translational modifications such as H3K9K14 acetylation, H3K4 trimethylation and H3K23 trimethylation are involved in the regulation of BAALC expression in AML cells (Franzoni et al., [@b13]). In animal models, inhibitory effects on OA have been observed after intra-articular injection of trichostatin A, an inhibitor of histone deacetylase (Chen et al., [@b6]). These observations show that cartilage cell degeneration might lead to epigenetic changes, resulting in altered BAALC levels in OA patients. Thus, OA prognosis and its correlation with BAALC are areas of current interest.

Although there have been no previous studies regarding the relationship between BAALC and OA, a study has shown variation in microRNA abundance based on differences in weight loads for each layer of articular cartilage in a bovine model. Non-weight-bearing regions show down-regulated expression of miR-148a, a microRNA that is associated with leukemia, compared with the expression level in weight-bearing regions (Dunn et al., [@b10]). miR-148a expression shows a negative correlation with *BAALC* gene expression (Langer et al., [@b28]), and high *BAALC* gene expression correlates with the presence of an early-stage marker of precursor cells. This observation suggests that cell proliferation is stimulated in weight-bearing regions of articular cartilage. Therefore, an increase in the amount of BAALC in OA patients (*p* = 0.051) could modulate cell proliferation in damaged cartilage.

PRDX6 is an enzyme that has both glutathione peroxidase and lysosomal-type phospholipase A2 activities, and also possesses an antioxidant activity. The link between OA and ROS is well known with ROS increasing in OA patients (Koorts et al., [@b25]; Xie et al., [@b48]). The expression of PRDX5, which belongs to the same peroxiredoxin family, increased significantly in OA cartilage. In other studies, the expression of PRDX5 has been suggested to increase as a protective measure against tissue damage caused by ROS (Wang et al., [@b40]).

In a proteomic analysis of cartilage extracts from mice, PRDX6 was detected, but the correlation between PRDX6 and OA was not studied (Wilson et al., [@b46]). However, we found that the amount of PRDX6 was significantly reduced in OA cartilage, compared with the control group, suggesting that protection against tissue damage from ROS by PRDX6 is prevented in OA. Taken together, these results strongly suggest that PRDX family members are involved in protection against damage caused to cartilage by ROS, and that these proteins may be applicable in therapeutic intervention. Our study also identified the utility of PRDX6 as a marker. No correlation was found between PRDX6 abundance and age, height, BMI, gender or Kellgren--Lawrence grade.

Based on previous studies, a correlation between OA and BMI is well known. The OA risk factor is a BMI of ≥30 kg/m^2^ in WHO research (Gudbergsen et al., [@b15]; Wills et al., [@b45]). However, average weight and BMI in Japan are low compared with those in Europe and the United States (WHO expert consultation, [@b43]). In our current study, average weight and BMI were 56 kg and 22 kg/m^2^, respectively. These values are obviously lower than the worldwide average. In addition, there was no correlation between OA and BMI because of the low number of patients with high BMI in the current study. For these reasons, we do not deny the correlation between OA and BMI.

In addition to cartilage-specific molecules such as CTX-II, CPII, C2C, HA, MMP-1, MMP-8 and MMP-13 (Conrozier et al., [@b8]), non-organ specific molecules such as fibulin-3 peptides (Henrotin et al., [@b16]), follistatin-like protein 1 (Wang et al., [@b42]), and C3 (Wang et al., [@b41]) are useful as OA biomarkers that can reflect OA pathology. In our current study, LECT2, BAALC and PRDX6 were not cartilage-specific proteins. Considering the above reports, we believe that these proteins may also be useful as OA biomarkers.

Because serum biomarkers are easy to measure continuously, they are considered useful for prognostication of OA. Furthermore, combined with diagnostic imaging results, the results of our study may assist OA diagnosis. LECT2 is a secreted protein that can be detected in serum (Sato et al., [@b36]). BAALC can also be detected in serum (Baldus et al., [@b3]). Although PRDX6 is also detected in serum, it is an enzyme and not a secreted protein (Zhang et al., [@b51]). As mentioned above, there is a high possibility that these proteins can be detected and measured in serum samples from OA patients. Therefore, they may be useful biomarkers for OA. As a next step, it will be important to perform large-scale research using serum from OA patients.

Of the previously identified OA markers such as CTX-II, C2C, COMP and HA, many are catabolic enzymes or fragments generated by proteolysis and/or degradation of the extracellular matrix. In addition to identifying COMP in OA cartilage, we confirmed variation in the expression of a molecule that could potentially function*via* autocrine or paracrine mechanisms in cartilage cells (LECT2), a molecule that could potentially function within cartilage cells (BAALC), and a molecule that has an antioxidant activity (PRDX6).

Conclusions {#ss10}
===========

In developed countries with an aging population, the number of individuals with OA is predicted to continue to rise. Given the sheer number of such individuals, the utility of a marker that can be easily measured in blood, urine or synovial fluids cannot be ignored. In the future, efficient selection of patients with a high potential risk for progressive joint destruction and application of intensive prevention measures may drastically reduce the number of patients with severe joint destruction. To this end, identification and evaluation of an easily measurable biomarker is imperative. Combination of conventional markers with newly identified markers, the variation of which was confirmed in this study, may improve diagnosis of the OA disease state and the capacity for prognosis. We believe that it is necessary to perform large-scale clinical research using serum from OA patients to investigate useful biomarkers in the near future.
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